BrainParrot

Revised MRPs of 1,364 Anti-Cancer Formulations Come into Effect from Today

GS2Full notePublished: · Updated:

Source: PIB (Press Information Bureau) · Read the original ↗

Summary

  • NPPA capped trade margins on the MRP of 137 anti-cancer drugs. It acted on the recommendations of a DGHS (Ministry of Health & Family Welfare) Expert Committee, with the notification dated 17 October 2026.
  • The revised MRPs took effect on 9 November 2026.
  • By 8 November, 85 companies had reported revised MRPs for 1,364 formulations covering 121 drugs.
  • The government expects consumer savings of ₹3,540.38 crore a year.

UPSC relevance: GS2 — Health / Social Justice; GS3 — Regulation of pricing

Key facts for Prelims

  • NPPA works under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
  • The expert committee that recommended the 137 drugs was constituted by the Directorate General of Health Services (Ministry of Health & Family Welfare).
  • The DPCO 2013 is issued under the Essential Commodities Act, 1955. Para 19 permits price fixation in public interest. TMR is the mechanism used.
  • Scheduled drugs (NLEM-based First Schedule) get ceiling prices. Non-scheduled drugs are subject to a 10% annual MRP-rise limit.
  • Consumer tools: the Pharma Sahi Daam mobile app and the NPPA website (nppa.gov.in). Grievances go to the Pharma Jan Samadhan portal. NPPA helpline: 1800-111-255.
  • No chemist or hospital pharmacy can charge above the revised MRP printed on the pack.
  • Related institutions: NLEM (Health Ministry), DGHS, DPCO 2013, NPPP 2012.

Data and details

  • 137 anti-cancer drugs are covered by the trade-margin cap. The notification is dated 17 October 2026, and revised MRPs are effective 9 November 2026.
  • As on 8 November 2026, 85 pharmaceutical companies reported revised MRPs for 1,364 formulations covering 121 drugs.
  • 679 brands reported price reductions of more than 50%.
  • The highest reported reduction is 96.45%.
  • Estimated annual consumer savings are ₹3,540.38 crore.
  • The company reporting is partial (as on 8 November). The count of 1,364 formulations and 121 drugs is lower than the 137 drugs notified.

Static–dynamic linkage

  • India regulates drug prices through the Drugs (Prices Control) Order (DPCO), 2013, issued under the Essential Commodities Act, 1955.
  • "Scheduled" drugs are those in the NLEM-based First Schedule. They get a ceiling price.
  • "Non-scheduled" drugs are priced freely by the manufacturer, subject to a 10% annual MRP-rise limit.
  • A Trade Margin Rationalisation (TMR) cap is a different tool. It limits the markup between the price to the retailer and the MRP.
  • This is how the State reaches high-markup drugs that sit outside price control, without fixing manufacturer prices.
  • The link to public policy is out-of-pocket expenditure on health, which is the major driver of impoverishment. Cancer care is a leading example.

Syllabus mapping: GS2 – Governance/Social Justice: Health; regulatory bodies | GS3 – Economy: Pricing regulation, pharma sector | Prelims – Economy/Polity (statutory and regulatory bodies)

Background primer

National Pharmaceutical Pricing Authority (NPPA)

What it is:
an independent body of experts and regulator for drug pricing. It is an attached office of the Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers.
Founded:
constituted by a Government of India Resolution dated 29 August 1997. The aim was to have a dedicated body to fix, revise and enforce prices of controlled drugs, because earlier price orders (DPCOs) lacked a dedicated monitoring and enforcement authority.
Members:
headed by a Chairperson; detailed composition not confirmed from a trusted source.

Drugs (Prices Control) Order, 2013

What it is:
the price-control order notified on 15 May 2013 under the Essential Commodities Act, 1955.

Additional context

  • Legal route. The 2026 cap was reported as 30% of MRP (excluding GST) under Para 19 of DPCO 2013. Manufacturers had to inform NPPA of revised prices within seven days of the notification.

  • Earlier pilot. The measure builds on NPPA's February 2019 pilot, which capped margins on 42 non-scheduled anti-cancer drugs. It cut the MRPs of 526 brands by up to 90%, with reported savings of about ₹984 crore a year.

  • Why non-scheduled drugs. NPPA has said that regulating scheduled drugs covers only about 16–17% of the pharma market. It has said arbitrary pricing through high markups persists in the non-scheduled segment.

  • Supreme Court. A GKToday explainer says the Supreme Court had flagged cases where the MRP of cancer medicines was up to ten times the price to retailers.

  • Permanence. The Parliamentary Standing Committee on Chemicals and Fertilizers reported on 6 August 2026. It noted that TMR has been used only as a pilot for certain anti-cancer medicines and COVID-19 devices, and that there is no timeframe to integrate a permanent TMR framework into DPCO 2013.

Mains dimensions

  • Health economics. Out-of-pocket spending on medicines pushes households into poverty. Targeting cancer drugs, where treatment is long, expensive and catastrophic, responds to a high-burden area.
  • Regulatory design. TMR is a lighter tool than full price control. It limits distributor and retailer markups instead of fixing manufacturer prices. The 2019 pilot (42 drugs) has now been widened to 137 drugs.
  • Scale of the effect. More than half of the reporting brands show a cut of over 50%, and the top cut is 96.45%. This suggests very large trade margins were embedded in the earlier MRPs.
  • Enforcement and awareness. The framework depends on price display, the Pharma Sahi Daam app, the Pharma Jan Samadhan grievance portal and a toll-free helpline. The notice that no chemist or hospital pharmacy can exceed the revised MRP places liability on the retail end of the chain.
  • Institutional and legal limits. The measure rests on the "extraordinary circumstances" power in Para 19, not a standing TMR provision. A permanent framework and wider data coverage remain open issues.
  • Federal and administrative linkage. The Health Ministry's DGHS expert committee recommends and the Chemicals & Fertilizers Ministry's NPPA implements. This is a case of inter-ministerial coordination.
  • Way forward. Embed TMR in DPCO and extend it to other chronic-disease drugs. Improve price data and monitoring. Pair it with generic promotion (Jan Aushadhi) and procurement reform.

Possible Mains question

**GS2, 15 marks:** "Out-of-pocket expenditure on medicines remains a major cause of impoverishment in India. Examine the regulatory tools available for drug price control and assess the role of Trade Margin Rationalisation in making cancer treatment affordable."

Related topics

  • National List of Essential Medicines (NLEM) and the DPCO Schedule-I
  • Essential Commodities Act, 1955
  • National Pharmaceutical Pricing Policy 2012
  • Jan Aushadhi (PMBJP) and Ayushman Bharat PM-JAY
  • Out-of-pocket expenditure and National Health Policy 2017
  • Parliamentary Standing Committees

Topics: GS2

How we write and check these notes →

All current affairs of 9 November 2026 → · UPSC Current Affairs